文献速递角膜与眼表疾病小儿眼科与斜弱视

儿童进展性圆锥角膜角膜胶原交联的长期安全性与有效性:7年随访

Long-term Safety and Efficacy of Corneal Collagen Crosslinking in a Pediatric Group With Progressive Keratoconus: A 7-year Follow-up.
PubMed 文献 · Am J Ophthalmol · 2023-01-20

前瞻性临床队列研究纳入74眼(58例,平均年龄13.0±2.1岁)行标准角膜交联,比较HPMC与Dextran核黄素。7年随访显示最大K值持续降低,82%眼UDVA和CDVA改善或稳定,两组视力与KC稳定性无统计学显著差异,但HPMC组角膜持续变薄。

要点

  • 标准CXL在儿童进展性KC中7年随访显示最大K值持续降低。
  • 82%眼UDVA和CDVA改善或稳定,1、2、3年CDVA差异有统计学意义。
  • HPMC组角膜持续变薄,Dextran组6个月时厚度均值回到基线。

核心结论

  • 标准CXL在儿童进展性KC中随访至7年可减少KC进展,82%眼UDVA和CDVA改善或稳定。
  • Dextran组与HPMC组在视力和KC稳定性方面无统计学显著差异。
  • HPMC组显示角膜持续变薄,作者对其在标准CXL中的使用提出担忧。

研究设计与样本

  • 前瞻性临床队列研究。
  • 共74眼(58例患者,45例男性,平均年龄13.0±2.1岁)行标准CXL,其中53眼使用HPMC、21眼使用Dextran。
  • 随访时间为基线、3和6个月及1、2、3、4、5、7年。

主要发现

  • UDVA和CDVA在所有随访期均改善,CDVA在1、2、3年差异有统计学意义。
  • 与基线相比,最大K值在整个7年随访期间降低。
  • 最薄角膜厚度均值在3个月时显著下降并保持较低;Dextran组最薄角膜厚度均值在术后6个月回到基线。
  • CXL后最大K值进展1.5D的眼比例为1.4%至14.6%,恶化见于术后4至7年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess effectiveness and safety of corneal crosslinking (CXL) to reduce keratoconus (KC) progression and improve visual acuity among children with progressive KC and to analyze the use of 20% dextran-based (Dextran) and 1% hydroxypropyl methylcellulose-based (HPMC) riboflavin. DESIGN: Prospective, clinical cohort study METHODS: Standard CXL (SCXL) was performed in 74 eyes (58 patients, 45 males, mean age 13.0 ± 2.1 years): 53 eyes with HPMC and 21 with Dextran. Examinations were performed at baseline, 3 and 6 months, and 1, 2, 3, 4, 5, and 7 years of follow-up, including uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), a complete ophthalmologic examination, anterior segment ocular coherence tomography, Scheimpflug corneal tomography, and specular microscopy. RESULTS: UDVA and CDVA improved at all periods with statistically significant differences in CDVA at 1, 2, and 3 years. Compared with baseline, maximum K (Max K) reduced throughout the 7-year follow-up. Mean thinnest pachymetry (Th Pachy) decreased significantly at 3 months and remained low; in the Dextran group, the Th Pachy mean value returned to baseline 6 months postoperatively. After CXL, 1.5 diopter progression in max K was 1.4% to 14.6% of eyes; worsening was found at 4 to 7 years postoperatively. CONCLUSION: SCXL reduced KC progression in children up to 7 years of follow-up and revealed improvement and stability of UDVA and CDVA in 82% of eyes. For visual acuity and KC stability, no statistically significant difference was observed between Dextran-HPMC. The HPMC group showed persistent cornea thinning, raising concerns about its use in SCXL.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Polido J, Araújo MEXDS, Wakamatsu TH, et al. Long-term Safety and Efficacy of Corneal Collagen Crosslinking in a Pediatric Group With Progressive Keratoconus: A 7-year Follow-up. Am J Ophthalmol. 2023. PMID: 36682518. doi:10.1016/j.ajo.2023.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。